Nancy S. Lurker's appointment to Alkermes' Board is viewed positively, bringing deep industry experience and commercial expertise. Her broad skills are expected to drive growth of existing products, portfolio expansion, and new product launches.
Alkermes' surplus of cash over debt and its ability to convert EBIT to free cash flow indicate a conservative balance sheet and low risk in its debt management.
Although Alkermes' share price has recently dipped, its long-term business trends are positive. Insider purchases, often seen as a good omen by investors, add further optimism.
アルカームスに関するコメント
コラムToday's pre-market stock movers: ANGO, SKIL, CXM, HPQ and more
• $アンジオダイナミクス(ANGO.US)$ +13.5%, $スキルソフト(SKIL.US)$ +3.26%, $スプリンクラー(CXM.US)$ +8.96%, $カズー・グループ(CZOO.US)$ +11.1%, $アポジー・エンタープライジズ(APOG.US)$ +3.3%, $リーバイ・ストラウス(LEVI.US)$ +1.7%, $コンステレーション・ブランズ(STZ.US)$ + 0.8%
• $モメンタス(MNTS.US)$ +36.9% (signed multiple launch agreements with Space Exploration Technologies Corp)
• $HPインク(HPQ.US)$ +10.1% (Berkshire Hathaway's Warren Buffett disclosed the purchase of mln sh...
Just got FDA approved and have another drug phase1/2 on 4 June!!
まだコメントはありません